Showing 129 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

Injectable & long-acting PrEP

The anti-HIV injection will be made in South Africa. It could cost between R600 and R800 a pop

Editor's pick
Bhekisisa
9 May 2023
PrEP science

PrEP and women A research briefing

About HIV
April 2023
Injectable & long-acting PrEP

Pharmaceutical corporation ViiV must provide transparency on life-saving HIV-prevention drug

Editor's pick
Médecins Sans Frontières
31 March 2023
Injectable & long-acting PrEP

Medicines Patent Pool signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of ViiV Healthcare’s innovative long-acting HIV prevention medicine

Editor's pick
Medicines Patent Pool
30 March 2023
Injectable & long-acting PrEP

Cabotegravir long-acting for PrEP registrations continue in Sub-Saharan Africa

Editor's pick
ViiV press release
29 March 2023
Injectable & long-acting PrEP

Black Gay Men and Trans Women Are Well Protected by Injectable PrEP

Editor's pick
POZ
21 March 2023
Injectable & long-acting HIV treatment

Top 5 stories on injectable HIV treatment and PrEP from CROI 2023

News
15 March 2023
New & experimental HIV treatments

Top 5 stories on new drugs for HIV prevention and treatment from CROI 2023

News
14 March 2023
Injectable & long-acting PrEP

CROI 2023: Islatravir implant for PrEP Video

March 2023
Injectable & long-acting PrEP

Experimental islatravir implants protect monkeys against HIV-like virus

News
1 March 2023
Injectable & long-acting PrEP

Long-Acting CAB for PrEP Acceptable, Safe in Adolescent Female Africans

Editor's pick
NATAP
27 February 2023
PrEP science

HIV infections acquired while on injectable PrEP may take a very long time to be spotted

News
27 February 2023
Injectable & long-acting PrEP

Modeling study shows that long-acting injectable cabotegravir has the potential to significantly reduce new HIV infections

Editor's pick
Clinton Health Access Initiative
23 February 2023
Injectable & long-acting PrEP

Good news for women and PrEP: quarterly dosing may work

News
23 February 2023
Injectable & long-acting PrEP

Large Benefit With Long-Acting PrEP in Black People, but Some HIV Risk Persists

Editor's pick
MedPage Today
22 February 2023
Injectable & long-acting PrEP

Cabotegravir long-acting PrEP out of reach for upper middle-income nations

News
8 February 2023
Injectable & long-acting PrEP

Study suggests side-effects and costs are biggest concerns for users of PrEP

Editor's pick
Medical Xpress
1 February 2023
PrEP policies & guidelines

US: Why Are We Delaying Coverage Of New HIV Prevention?

Editor's pick
Health Affairs
26 January 2023
Injectable & long-acting PrEP

Long-acting PrEP could reduce HIV incidence, AIDS deaths in sub-Saharan Africa

Editor's pick
Healio
25 January 2023
The search for an HIV prevention vaccine

Closure of HIV vaccine study shows how far we have to go

News
19 January 2023
Injectable & long-acting PrEP

Uganda: Drug Could Beat Back HIV — If People Could Get It

Editor's pick
Global Press Journal
26 December 2022
PrEP

Uganda moves forward on PrEP vaginal ring and injection

Editor's pick
Be In The Know
20 December 2022
Injectable & long-acting PrEP

HIVMA welcomes the U.S. Preventive Services Task Force Release of Updated PrEP Rating

Editor's pick
HIV Medicine Association
19 December 2022
PrEP policies & guidelines

PrEP4ALL Applauds The Updated USPSTF Grading Adding Long-Acting PrEP, But Demands Gov’t Action to Ensure Access

Editor's pick
PrEP4All
13 December 2022